|Bid||3,205.50 x N/A|
|Ask||3,217.00 x N/A|
|Day's Range||3,210.00 - 3,250.00|
|52 Week Range||2,171.50 - 4,028.75|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||25.54|
|Forward Dividend & Yield||63.32 (1.95%)|
|Ex-Dividend Date||Nov 17, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GSK.BA
GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript February 1, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the analyst call of GSK Fourth Quarter 2020 Results. I will now hand you over to Nick Stone, Head of Global Investor Relations, who will introduce today’s session. Nick Stone: Thank you, operator. Hello, everyone. […]
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
The U.S. Food and Drug Administration (FDA) on Wednesday approved GSK Plc's drug as the first oral treatment for anemia caused by chronic kidney disease in adults who have been on dialysis for at least four months. The drug Jesduvroq comes with the boxed warning for increased thrombotic vascular events, including death, heart attack, stroke, and blood clots in the lungs, legs, or dialysis access site. The warnings and precautions also include a risk of hospitalization for heart failure, worsening increase of blood pressure, stomach erosions, and gastrointestinal bleeding.